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Abstract
Production of the iron regulatory peptide hepcidin is tightly controlled by a network of pro-
teins in hepatocytes that sense levels of iron in the circulation (as diferric-transferrin) and in
tissues (in ferritin). Human studies show high variability in the normal range of serum hepci-
din levels. We have postulated that this may, in part, be related to inter-individual variability
in the expression of genes in the iron sensing pathway, potentially governed by epigenetic
factors. Here, we have investigated whether genes encoding hepatic iron sensing proteins
and hepcidin are regulated by DNA methylation. Experiments were performed on two
human hepatoma cell lines, HepG2 cells and Huh7 cells. Basal expression of TFR2 and
HAMP was significantly lower in Huh7 cells compared with HepG2 cells. Analysis of bisul-
phite-converted DNA from Huh7 cells revealed partial methylation of TFR2 (alpha tran-
script), which could result in gene silencing. Demethylation using 5-aza-2’-deoxycitidine
(AZA) increased TFR2 mRNA expression in Huh7. PCR analysis of bisulphite-converted
HAMP promoter DNA, using methylation-specific primers, revealed no differences between
cell lines. However, HAMP mRNA expression in Huh7 was increased by AZA treatment,
suggesting that methylation of one or more iron sensing genes may indirectly influence
HAMP expression. Our study provides evidence that DNA methylation might control expres-
sion of HAMP and other hepatic iron sensing genes, and indicates that epigenetic influences
on iron homeostasis warrant further investigation.
Introduction
Iron homeostasis is maintained by a network of proteins in hepatocytes, which sense changes
in circulating and cellular levels of iron. Downstream signalling from these sensors leads to the
regulated production of hepcidin (reviewed in [1]). Once released from hepatocytes, serum
hepcidin acts as a negative regulator of iron export from a number of cell types, including
enterocytes and macrophages, by decreasing expression of the iron transport protein ferropor-
tin [2–5]. In addition, in enterocytes, hepcidin limits iron absorption from diet through down-
regulation of DMT1 [5–8].
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In hepatocytes, increased cellular iron activates the bone morphogenetic protein (BMP) sig-
nalling pathway, which encompasses the ligand BMP6, BMP receptors and the co-receptor
hemojuvelin (HJV), and induces the production of hepcidin via the SMAD signalling pathway
[9,10]. The protein network which senses changes in serum iron levels (detected as changes in
transferrin (Tf) saturation) and translates this information to produce appropriate levels of
hepcidin is complex. At low Tf saturation levels, the hereditary haemochromatosis protein
HFE and transferrin receptor 1 (TfR1) exist as a complex on the plasma membrane. However,
at increased saturation levels, diferric-Tf competes with HFE for binding to TfR1. This causes
HFE to dissociate from TfR1 and bind to a second transferrin receptor (TfR2). HFE/TfR2/
diferric-Tf binding initiates an iron sensing pathway leading to increased production of hepci-
din [11].
The TFR2 gene contains two promoter regions and encodes two receptor isoforms. TFR2-
alpha transcript encodes the full length receptor and is expressed on the cell surface of hepato-
cytes, erythroid progenitors and peripheral blood mononuclear cells [12]. The TFR2-beta tran-
script is a truncated form which lacks the membrane spanning domain and is highly expressed
in spleen, brain and heart [12]. Its physiological role is unclear, but may be involved in regula-
tion of ferroportin in splenic macrophages [13]. The involvement of each of the TFR2 tran-
scripts in iron sensing and the regulation of hepcidin production has not been studied
previously and we have addressed this in our current work.
Mutations in TFR2 give rise to type III haemochromatosis [14], which is characterised by
liver iron loading and inappropriately low hepcidin levels [15,16]. Furthermore, evidence from
knockout studies in mice demonstrates that deletion of TFR2 [17,18], HFE [17,18], HFE2
(HJV) [19,20], or BMP6 [10] leads to inappropriately low HAMP (the gene encoding hepcidin)
expression and liver iron loading. Taken together this suggests that each of these iron sensing
elements has a specific role to play in the appropriate production of hepcidin. Interestingly,
while the HFE/TfR2 and BMP signalling pathways regulating HAMP expression may operate
independently of each other [21–23], there is also evidence for interaction between these sens-
ing networks [17,24].
In addition to modulation by iron, HAMP expression is regulated by a variety of other sig-
nals including adipokines [25], pro-inflammatory cytokines [26–29], and hypoxia [30–34].
The normal range of serum hepcidin levels in the healthy population is highly heterogeneous
[35–37]. While age and gender are significant factors in this distribution, there is still consider-
able variability (by as much as 50-fold) within population groups. The basis for this is unclear,
but it could be related to the non-iron factors identified above (cytokine levels, etc.) or to
inter-individual variability in the expression of genes in the iron sensing pathway. Gene
expression at an individual level may be controlled by a number of genetic or epigenetic fac-
tors. One possible mechanism is through DNA methylation, which occurs at CG sites, result-
ing in the formation of 5-methylcytosine. CpG-rich regions, known as CpG islands, often
occur within the promoter regions of genes, and when methylated result in the repression of
gene expression [38]. In this study we have explored ENCODE DNA methylation data to iden-
tify putative methylation target sites in the promoter regions of iron sensing genes and HAMP,
and assessed the effects of demethylation on mRNA expression of these genes in human hepa-
toma cell lines.
Materials & methods
Cell culture
HepG2 (ATCC) and Huh7 (gift from Prof. S. Srai, UCL) hepatoma cells were cultured in Dul-
becco’s modified Eagle medium containing 10% fetal bovine serum, 100 units/ml penicillin,
DNA methylation and HAMP expression
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100 μg/ml streptomycin, 2 mM L-glutamine and 1% non-essential amino acid solution (all
purchased from Thermo Fisher Scientific, UK). For experiments, cells were seeded into 6-well
plates at a density of 1 x 105 cells/cm2. In some experiments cells were treated with 5-aza-2’-
deoxycitidine (AZA, 5 μM) for 72 hours; medium containing AZA was replaced every 24
hours.
Quantitative real-time (qRT)-PCR
RNA isolated from hepatic cells was converted to cDNA using a High Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Scientific). Expression of TFR2 alpha transcript, TFR2 beta
transcript, HAMP, HFE, BMP6, HFE2 (HJV) and B2M (reference gene) was analysed using
Fast SYBR green Master Mix (Thermo Fisher Scientific) and a ABI Prism 7500 FAST sequence
detection system (Applied Biosystems). Primer sequences are given in Table 1. Data were ana-
lysed using the 2-ΔΔCt method [39].
Methylation PCR
DNA from HepG2 and Huh7 cells was subject to bisulphite conversion using EZ DNA Meth-
ylation-Gold™ kit (Zymo Research) according to the manufacturer’s instructions. For analysis
of the TFR2 alpha promoter, a 246 bp fragment containing the whole of exon 1, plus the 5’
flanking region and intron 1 (base pairs -154 to +92, relative to the translation start site), was
amplified using bisulphite-specific primers (Table 1, designed using MethPrimer; www.
urogene.org/cgi-bin/methprimer/methprimer.cgi). The amplicon contained a ClaI restriction
digest site (ATCGAT) which allowed the PCR product to be cut into two fragments (138
and 108 bp, respectively) if the CpG within the restriction enzyme recognition site was methyl-
ated. Aliquots of ClaI-digested and undigested PCR products were resolved on 2% agarose-
ethidium bromide gels. Further aliquots of the full amplicon were cloned into E. coli using a
TOPO TA Cloning Kit (Invitrogen). Positive colonies were selected and DNA extracted and
sequenced (ABI 3730xl DNA Analyser).
For analysis of the HAMP promoter, no suitable bisulphite-specific primers could be
designed. Instead we designed methylation-specific primers (Table 1) that would bind to either
the predicated methylated or unmethylated DNA sequences within the bisulphite-converted
HAMP promoter. Primers targeted identical regions in the HAMP promoter, and differed only
Table 1. PCR primers sequences.
Primer Forward sequence Reverse Sequence
B2M RT CCA CTG AAA AAG ATG AGT ATG CCT CCA ATC CAA ATG CGG CAT CTT CA
HAMP RT CTG CAA CCC CAG GAC AGA G GGA ATA AAT AAG GAA GGG AGG GG
TFR2-α RT GTC AGT GAG GAT GTC AA CCA CAC GTG GTC CAG CTT CT
TFR2-β RT CCA GAA AAG TCC CCA CCT C TGC TCT CCG ACC TTC CC
HFE RT AGA ACA GGG CCT ACC TGG AG TGT GTC ACC TTC ACC AAA GG
HFE2 (HJV) RT GGA GCT TGG CCT CTA CTG GA ATG GTG AGC TTC CGG GTG
BMP6 RT CCG TGT AGT ATG GGC CTC AGA TCA CAA CCC ACA GAT TGC TAG T
TFR2-α BIS GGG GGT TGA GGG ATT AGA GAA CCA AAA CTA TAC CCC CAC CCT TAA AA
HAMP Met TTT TGT TTT CGT TTA TTT TTT TCG T AAA CTC AAT ACC ATC GTA CCG TC
HAMP Unmet TTT TGT TTT TGT TTA TTT TTT TTG T AAA AAC TCA ATA CCA TCA TAC CAT
RT = qRT-PCR primer; BIS = primers for bisulphite-converted DNA; Met = specific primers for methylated
bisulphite-converted DNA; Unmet = specific primers for unmethylated bisulphite-converted DNA.
https://doi.org/10.1371/journal.pone.0197863.t001
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at two C/T bases in each of the forward and reverse primers. Analysis was carried out using
qRT-PCR.
Statistics
Data are presented as mean ± S.E.M. Data were analysed using Mann-Whitney tests and dif-
ferences with p< 0.05 considered statistically significant. Linear regression analysis was per-
formed using Sigmaplot (version 13, Systat Software Inc., UK).
Results
The relative basal RNA expression levels of iron sensing genes were measured in HepG2 and
Huh7 cells, respectively (Fig 1). Expression of HAMP and TFR2 alpha was significantly greater
in HepG2 cells compared with Huh7 cells (Fig 1A and 1B). There were no significant differ-
ences in levels of TFR2 beta (Fig 1C), HFE (Fig 1D) or BMP6 (Fig 1E) between the two cell
lines. HFE2 (HJV) levels were significantly higher in Huh7 cells (Fig 1F).
Fig 1. Baseline expression of iron sensing genes in HepG2 and Huh7 cells. mRNA expression of (a) HAMP, (b) TFR2 alpha, transcript, (c) TFR2 beta transcript, (d)
HFE, (e) BMP6 and (f) HFE2 (HJV) were measured by RT-PCR. Data are means ± SEM of 5–8 observations in each group and were normalised to expression in HepG2
cells.  P< 0.02 (Mann-Whitney test).
https://doi.org/10.1371/journal.pone.0197863.g001
DNA methylation and HAMP expression
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We hypothesised that differences in expression may be related to cell-specific methylation
of the gene promoters. To investigate this possibility, we interrogated data from the ENCODE
project [40] on the University of California Santa Cruz Genome Browser. We restricted our
search to CpGs within the 5’ promoter for each gene of interest, since methylation in this
region has been show to repress gene expression [38]. At least one CpG was identified in the
promoter region of each gene of interest and β-values for the degree of methylation are
reported in Table 2. Data were available for experiments with human hepatocytes and with
HepG2 cells. In the context of the differences observed in basal expression of TFR2 alpha and
HAMP in the hepatic cell lines, it was interesting to note that there was some variation in the
degree of methylation of CpGs in both the TFR2 alpha and HAMP gene promoters in hepato-
cytes and HepG2 cells (Table 2).
To determine whether the TFR2 alpha and HAMP promoters were methylated in Huh7
hepatoma cells, and to confirm their methylation status in HepG2 cells, we carried out bisul-
phite conversion of DNA and used specific primers to interrogate the CpGs within each pro-
moter that corresponded to the 450K probe sites (Illumina Infinium HumanMethylation450K
BeadChip) from the ENCODE project. For TFR2 alpha, the amplified promoter fragment con-
tained a potential ClaI restriction digest site if the C of the relevant CpG site was retained fol-
lowing bisulphite treatment (i.e., methylated). Following ClaI treatment only the full-length
TFR2 alpha PCR product (246 bp) was identified in HepG2 cells, whereas three fragments
(246; 138 and 108 bp) were detected in Huh7 cells (Fig 2A) indicating that the TFR2 alpha pro-
moter site was unmethylated in HepG2 cells, but partially methylated in Huh7 cells. K562 cells
(ENCODE β-values: cg10681065, 0.04; cg04423314, 0.06) and Jurkat cells (ENCODE β-values:
cg10681065, 0.88; cg04423314, 0.69) were used as positive and negative methylation controls,
respectively. Selection of these cell lines as controls was based on previously published data
showing high expression of TFR2 alpha in K562 cells, but low expression levels in Jurkat cells
[12]. Only the full-length TFR2 alpha PCR product (246 bp) was present in K562 cells, whereas
the ClaI digested fragments (138 and 108 bp) predominated in Jurkat cells (Fig 2A). To further
investigate the cell-specific difference in TFR2 alpha promoter methylation, we subjected
amplicons from all cell lines to bisulphite sequencing. Five CpG sites were present in the TFR2
alpha amplicon. All sequenced CpGs in K562 cells and the majority of CpGs in HepG2 cells
Table 2. Beta-values from ENCODE database showing degree of methylation of CpG sites in promoters of iron sensing genes.
Beta-values
Gene of Interest CpG identifier HepG2 cells Hepatocytes
TfR2α cg10681065 0.09 0.28
cg04423314 0.09 0.28
TfR2β cg04499151 0.96 0.70
HFE cg06892726 0.08 0.10
cg05569784 0.21 0.30
HJV cg00953211 0.22 0.13
cg00987513 0.73 0.27
cg06589885 0.13 0.05
BMP6 cg22505205 0.50 0.13
cg22541378 0.24 0.03
cg03447931 0.32 0.02
HAMP cg26283059 0.12 0.27
cg17907567 0.10 0.25
cg23677000 0.13 0.21
https://doi.org/10.1371/journal.pone.0197863.t002
DNA methylation and HAMP expression
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were unmethylated (Fig 2B). In contrast, 95% of CpG dinucleotides in Jurkat cells and more
than 50% of CpGs in Huh7 cells were methylated.
qRT-PCR analysis of the HAMP promoter using combinations of methylated and unmethy-
lated sequence-specific primers revealed no significant differences between HepG2 cells and
Huh7 cells for each primer combination (Fig 3). Melt curves indicated only a single PCR
product was generated with each of the primer combinations. Lowest Ct values (and therefore
highest levels) were observed using the methylated forward: unmethylated reverse primer
combination (mean Ct values: 30.6, HepG2; 30.4, Huh7). There was no effect of the demethyl-
ating agent 5-deoxy-2’-azacytidine (AZA) on amplicon levels in either cell line using the meth-
ylated forward: unmethylated reverse primer combination (HepG2 cells (normalised to
control values): control 1.0 ± 0.1; AZA 0.9 ± 0.1; n = 4 for both groups. Huh7 (normalised to
control values): control 1.0 ± 0.1; AZA 1.0 ± 0.3; n = 4 for both groups). Since there were no
differences in amplicon levels in the presence or absence of AZA in HepG2 and Huh7 cells, we
concluded that there was no cell-specific methylation within this region of the HAMP pro-
moter and therefore amplicons were not subjected to full bisulphite sequencing.
Next we investigated the effects of AZA on the expression of iron sensing genes in HepG2
cells and Huh7 cells. There was no effect of AZA on expression of HAMP and TFR2 alpha in
HepG2 cells (Fig 4A and 4B); however, expression of both genes was significantly increased by
AZA treatment in Huh7 cells (Fig 5A and 5B). TFR2 beta (Fig 4C; Fig 5C) and BMP6 (Fig 4E;
Fig 5E) expression was significantly increased by AZA treatment in both cell lines. HFE2
(HJV) expression was increased in AZA-treated HepG2 cells only (Fig 4F; Fig 5F). There was
no effect of AZA on HFE expression in either cell line (Fig 4D; Fig 5D).
Our data indicated that cellular expression and regulation of HAMP and TFR2 alpha fol-
lowed a similar pattern; i.e., highest expression in HepG2 cells (Fig 1A and 1B) and up-regula-
tion by AZA-treatment only in Huh7 cells (Fig 5A and 5B). However, while there were clear
differences in methylation of TFR2 alpha in HepG2 and Huh7 cells (Fig 2), there was no evi-
dence for cell-specific differences in HAMP promoter methylation at documented CpG sites
(Fig 3, Table 2). We therefore investigated the possibility that changes in expression of one or
more of the iron sensing genes might indirectly influence HAMP expression. In HepG2 cells
there was significant positive correlation between HAMP and TFR2 alpha, and HFE (Fig 6).
We carried out multiple linear regression to identify the variables which most significantly pre-
dict HAMP expression and found that HFE was the only significant predictor of HAMP
mRNA levels (P<0.005). In contrast, in Huh7 cells there was significant correlation between
HAMP and all iron sensing genes (i.e., TFR2 alpha, TFR2 beta, HFE, BMP6 and HFE2 (HJV);
Fig 7). Multivariate analysis revealed that BMP6 (P<0.001) and HFE2 (HJV) (P<0.03) were
the only significant predictors of HAMP expression in Huh7 cells.
Discussion
In this study we employed two well-characterised human hepatoma cell lines, HepG2 and
Huh7 cells, to investigate the putative effects of methylation on expression of hepatic iron
Fig 2. Methylation of TFR2 alpha promoter in human cell lines. A 246-bp fragment of the human TFR2 alpha promoter was generated by PCR.
Amplicons contained a ClaI restriction digest site which will cut the amplicon into 138 & 108 bp fragments if the CpG within the digest site is
methylated. Agarose gel (a) shows representative bands from uncut (U; water replacing enzyme) and ClaI-digested bisulphite-converted DNA
from K562, HepG2, Huh7 and Jurkat cells. The arrow indicates the position of the full length amplicon (246 bp);  indicates the position of the
ClaI digested fragments (138 & 108 bp). The cartoon depicts a representation of TFR2 alpha gene organization and the 246 bp PCR amplicon (b).
The 5’ upstream flanking region (from -152 bp relative to the translation start site) and intron 1 (downstream to +92 bp relative to the translation
site) are shown as lines; exon 1 containing the promoter and the translated region are shown as boxes. The vertical arrow denotes the ClaI digest
site. Horizontal lines below represent bisulphite sequencing of individual amplicons in each cell line. Open circles indicate unmethylated CpGs,
filled circles represent methylated CpGs.
https://doi.org/10.1371/journal.pone.0197863.g002
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sensing genes. HepG2 cells were originally derived from a well-differentiated hepatocellular
carcinoma [41], which displays a high level of morphological and functional differentiation in
vitro. Huh7 hepatoma cells were derived from a Japanese patient [42] and it has been shown
that these cells contain a mutated form of HFE [43]. Given that HFE is required for iron sens-
ing and appropriate control of HAMP expression [17,18], we hypothesized that iron sensing
and HAMP expression would differ in the two model cell lines.
Basal expression of TFR2 alpha and HAMP was significantly greater in HepG2 cells than
Huh7 cells. Differential tissue expression of TFR2 isoforms has been well documented [12].
TFR2 alpha is the predominant isoform in liver and blood mononuclear cells, and is highly
Fig 3. Methylation ofHAMP promoter. Bisulphite-converted DNA from HepG2 and Huh7 was subjected to qRT-PCR
using a combination of primers specific for methylated and unmethylated sequences. Data are presented as relative levels;
ΔCt relative to the methylated forward: methylated reverse primer set (M-M) for HepG2 cells.
https://doi.org/10.1371/journal.pone.0197863.g003
DNA methylation and HAMP expression
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expressed in associated tumour cell lines, e.g. HepG2 hepatoma cells and K562 erythroleukae-
mia cells. In contrast, highest expression of TFR2 beta was observed in spleen and T-cell leu-
kaemia cell lines, e.g., Jurkat cells; these cells also had low expression of TFR2 alpha [12]. One
explanation for the differential expression patterns of the TFR2 transcripts might be regulation
at the level of DNA methylation. To investigate this possibility, we used data from the
ENCODE project [40] including the methylation of specific CpG dinucleotides from experi-
ments using the Illumina Infinium HumanMethylation450K BeadChip array platform. We
focussed on CpGs in the 5’ promoter of TFR2, since methylation of CpGs in gene promoters is
associated with silencing of gene expression [38]. For TFR2 alpha, the methylation pattern
from ENCODE (Table 2) and our bisulphite sequencing analysis (Fig 2) showed that CpGs
within the TFR2 alpha promoter were unmethylated in K562 cells and HepG2 cells, but meth-
ylated in Jurkat cells. These findings are consistent with previously published mRNA expres-
sion data showing high expression of the TFR2 alpha transcript in K562 and HepG2 cells, but
Fig 4. Effect of AZA on iron sensing gene expression in HepG2 cells. Cells were grown in the presence or absence of the global demethylating agent AZA (5 μM,
72 h). Expression of (a) HAMP, (b) TFR2 alpha, transcript, (c) TFR2 beta transcript, (d) HFE, (e) BMP6 and (f) HFE2 (HJV) were measured by RT-PCR. Data have been
normalised to the control group and are presented as mean ± SEM of 7–8 observations in each group. Data were analysed using Mann-Whitney tests.  P< 0.005;
 P< 0.03.
https://doi.org/10.1371/journal.pone.0197863.g004
DNA methylation and HAMP expression
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low expression in Jurkat cells [12]. Interestingly, our data demonstrated that the TFR2 alpha
promoter was partially methylated in Huh7, and this was associated with significantly lower
basal TFR2 alpha mRNA expression in Huh7 cells compared with HepG2 (Fig 1B). ENCODE
data for HepG2 cells and hepatocytes (Table 2) and our own analysis in Huh7 cells (56% meth-
ylation of promoter CpG dinucleotides) found significant methylation of the TFR2 beta pro-
moter, which may account for low expression of this transcript in both HepG2 and Huh7 cells.
Together, we have evidence that differences in DNA methylation are strongly associated with
tissue-specific expression of the TFR2 isoforms.
The tissue-specific epigenetic control of TFR2 observed here points to tissue-specific func-
tions of the isoforms in the regulation of iron homeostasis. In addition to its well-documented
role in hepatic iron sensing, TfR2 is a component of the erythropoietin receptor signalling
complex and is required for efficient erythropoiesis [44]. Haematopoietic deletion of Tfr2 in
mice results in impaired erythroid differentiation [45,46]. High expression of TFR2 in ery-
throid cells [47] and its role in erythroid differentiation have led to speculation of a clinically
Fig 5. Effect of AZA on iron sensing gene expression in Huh7 cells. Cells were grown in the presence or absence of the global demethylating agent AZA (5 μM, 72 h).
Expression of (a) HAMP, (b) TFR2 alpha, transcript, (c) TFR2 beta transcript, (d) HFE, (e) BMP6 and (f) HFE2 (HJV) were measured by RT-PCR. Data have been
normalised to the control group and are presented as mean ± SEM of 9–14 observations in each group. Data were analysed using Mann-Whitney tests.  P< 0.01.
https://doi.org/10.1371/journal.pone.0197863.g005
DNA methylation and HAMP expression
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relevant role in haematological disorders such as myelodysplastic syndrome (MDS) and acute
myeloid leukaemia (AML). In support of this, a recent retrospective analysis of samples from
patients with MDS found that expression of TFR2 alpha and TFR2 beta was significantly more
variable in MDS samples than in non-malignant bone marrow samples. Furthermore, low
expression of both TFR2 transcripts was associated with poorer survival rates in patients with
myelodysplastic syndrome with excess blasts than for those with normal to high TFR2 levels
[48]. Similarly, a study in patients with AML found higher expression of both TFR2 transcripts
was associated with significantly longer survival rates [49]. Interestingly, aberrant DNA meth-
ylation is the dominant epigenetic alteration in MDS [50] and DNA methyltransferase inhibi-
tors such as azacitidine are approved as treatment strategies in patients with MDS [51].
HAMP expression is also known to be tissue specific with highest expression in liver [52]
and lower levels present in other tissues including adipose and peripheral blood mononuclear
cells [53,54]. ENCODE data suggest that HAMP promoter CpG sequences adjacent to the
translation start site are unmethylated in HepG2 cells (Table 2), but are partially methylated in
both K562 and Jurkat cells (β-scores: cg26283059, 0.31—K562, 0.72—Jurkat; cg17907567, 0.31
—K562, 0.45—Jurkat). This is consistent with relatively low expression of HAMP in peripheral
blood mononuclear cells compared to hepatic cells [54], and may indicate a role for methyla-
tion in determining cell- and tissue-specific expression of HAMP. To determine whether
methylation accounted for the observed differences in basal expression of HAMP between
HepG2 and Huh7 cells we analysed the region of the promoter containing the CpG dinucleo-
tides cg17907567, cg23677000 and cg26283059. These CpGs are unmethylated in HepG2 cells
Fig 6. Correlation between iron sensing genes andHAMP in HepG2 cells. ΔCt values (using B2M as the reference gene) from control and AZA-treated cells were
plotted for each gene of interest vs HAMP. Data were analysed using linear regression.
https://doi.org/10.1371/journal.pone.0197863.g006
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(Table 2) and our studies suggest that there is no difference in methylation between HepG2
and Huh7 cells. In summary, our analysis does not support the hypothesis that differential
methylation of this region of the HAMP promoter explains the differences in basal expression
of HAMP between HepG2 and Huh7 cells.
To assess the effects of methylation on HAMP and TFR2 alpha mRNA expression we
treated cells with the 5-aza-2’deoxycitidine (AZA), which inhibits DNA methyltransferase
activity and results in global DNA demethylation [55]. AZA treatment increased TFR2 alpha
mRNA expression in Huh7 cells, but not in HepG2 cells. Taken together, our data and those
from ENCODE suggest that differential expression of TFR2 alpha between HepG2 cells and
Huh7 cells is mediated by methylation of promoter CpG dinucleotides. Furthermore, this is
also a likely explanation for tissue-specific expression of TfR2 isoforms demonstrated previ-
ously [12]. Expression of TFR2 beta and BMP6 was increased in both HepG2 and Huh7 cells,
and HFE2 (HJV) was elevated in HepG2 cells following AZA treatment indicating that methyl-
ation plays an important role in regulating the expression of a number of iron sensing genes.
AZA treatment significantly increased HAMP expression in Huh7 cells, but did not alter
HAMP levels in HepG2 cells. Interestingly, a recent report has shown that HAMP expression is
supressed in hepatocellular carcinoma through hypermethylation of CpGs within the gene
promoter [56]. These findings are in contrast to the data presented here. However, it is impor-
tant to note that the HAMP promoter region analysed by Udali et al. (-940 to -398 bp relative
to the translation start site) [56], did not overlap with the promoter amplicon studied in our
analysis (-186 to +14 bp relative to the translation start site). It is possible therefore that
Fig 7. Correlation between iron sensing genes andHAMP in Huh7 cells. ΔCt values (using B2M as the reference gene) from control and AZA-treated cells were
plotted for each gene of interest vs HAMP. Data were analysed using linear regression.
https://doi.org/10.1371/journal.pone.0197863.g007
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hypermethylation within the distal promoter modulates HAMP expression. Moreover, it is
possible that epigenetic silencing of elements within one or more of the iron signalling path-
ways may contribute to decreased HAMP expression. For example, SOSTDC1, an inhibitor of
BMP 2, 4 and 7 activity, decreases SMAD-signalling and subsequent hepcidin secretion in
prostate epithelial cells [57]. Interestingly in prostate cancer the SOSTDC1 gene promoter is
highly methylated leading to suppression of gene transcription, and this is associated with
increased HAMP expression and poorer prognosis in patients with prostate tumours [57].
A further possibility is that differential methylation of one or more of the hepatic iron sens-
ing genes could have an indirect effect on HAMP expression. Our previous work shows that
TFR2 mRNA correlates significantly with HAMP expression levels in human primary hepato-
cytes [58], while others have shown strong correlation between HFE and HAMP in HepG2
cells [59]. Here we found a significant correlation between levels of both TFR2 alpha and HFE,
and HAMP in HepG2 cells, with HFE being the most significant predictor of HAMP expres-
sion. Interestingly, while there is significant positive correlation between HAMP and each indi-
vidual iron sensing gene in Huh7 cells, multivariate analysis showed HFE2 (HJV) and BMP6 to
be the only significant predictors of HAMP. This divergence between the iron sensing path-
ways that correlate with HAMP expression in HepG2 and Huh7 cells is perhaps not surprising
given that there is a mutation in the HFE gene in Huh7 cells [43], which alters the conforma-
tion of the α3 domain of the mature protein. TfR2 interacts with the HFE α3 domain [60], and
therefore this mutation might silence downstream signalling pathways in Huh7 cells which
regulate HAMP expression. Similarly, the very low basal expression of HFE2 (HJV) in HepG2
cells, due at least in part to DNA methylation, is likely to dampen BMP/SMAD signalling in
these cells. Interestingly, in patients with MDS, the HFE2 promoter in bone marrow cells was
found to be hypermethylated. Treatment with AZA increased HFE2 expression and this was
associated with elevated serum hepcidin levels [61]. Taken together, our data suggest that
HFE/TfR2 signalling predominates as the iron sensing pathway in HepG2 cells, while the
BMP/HJV/SMAD pathway is dominant in Huh7 cells. Key iron sensing genes in both cell
lines may be silenced by DNA methylation and this may have an important bearing on HAMP
expression.
In summary, our study provides evidence for a role of DNA methylation in controlling
hepatic iron sensing and the production of hepcidin. Serum hepcidin levels in the healthy pop-
ulation are highly heterogeneous [35–37] and differential patterns of DNA methylation may
be important in determining the variability in iron status and hepcidin production at a popula-
tion level. This possibility remains to be explored. It has been demonstrated recently that there
is widespread inter-individual epigenetic variation, including DNA methylation, in human
neutrophils from healthy individuals, which might relate to phenotypic differences and poten-
tially susceptibility to a range of diseases [62]. The epigenetic influences on iron homeostasis
and the risk of developing iron metabolism disorders may be similarly linked and this possibil-
ity warrants further investigation.
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